# L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

> **NCT02631109** · PHASE3 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis

## Interventions

- **DRUG:** Pegaspargase
- **DRUG:** doxorubicin
- **DRUG:** etoposide
- **DRUG:** methylprednisolone

## Key facts

- **NCT ID:** NCT02631109
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2017-11
- **Final completion:** 2019-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2016-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631109, "L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02631109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*